The National Institute of Neurological Disorders and Stroke (NINDS), under the Department of Health and Human Services, is reissuing the funding opportunity for NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) aimed at facilitating the commercialization of pre-clinical research. This program addresses the "Valley of Death," where critical funding gaps exist between SBIR/STTR Phase II awards and commercialization. The initiative seeks to encourage partnerships between small business concerns (SBCs) and third-party investors, especially for projects targeting small markets, including rare diseases and pediatric populations. Key requirements include a Plan for Enhancing Diverse Perspectives (PEDP), independent third-party funding equivalents to the NINDS funds requested, and adherence to rigorous scientific standards. Applications are due between September 2024 and April 2027, with a budget cap of $2,045,816 for projects lasting up to three years. The document outlines eligibility preferences, application submission guidelines through Grants.gov, and evaluation criteria focusing on significance, innovation, and investigator qualifications, reinforcing the importance of diverse perspectives in research endeavors. This opportunity emphasizes support for diverse and potentially underrepresented groups in biomedical research to foster innovation and improve public health outcomes.